摘要
目的探讨辛伐他汀对慢性阻塞性肺疾病(COPD)患者鼻灌洗液、痰液和血清中炎症细胞和(或)炎症递质与临床指标的影响。方法选择COPD缓解期患者37例,给予常规治疗20例,辛伐他汀40mg/d治疗17例,比较治疗前和治疗4周患者鼻灌洗液和痰中细胞数、中性粒细胞百分比(N%)和IL-8、IL-6浓度,检测血清CRP、IL-8、IL-6及TC和LDL—C浓度,并观察肺功能、生活质量评分(SNOT-20)、呼吸问卷(SGRQ)评分的变化。结果4周后辛伐他汀组鼻灌洗液和痰中细胞总数、N%、IL-8、IL-6[鼻灌洗液:(0.7±0.3)×10^7/L,(41.1±10.9)%,(105.8±74.5)ng/L,(3.8±1.6)ng/L;痰:(0.8±0.3)×10^9/L,(56.6±9.6)%,(2565.5±831.9)ng/L,(109.8±42.3)ng/L]较治疗前[鼻灌洗液:(0.8±0.3)×10^7/L、(43.2±10.8)%、(107.6±86.3)ng/L、(4.1±1.9)ng/L;痰:(0.8±0.3)×10^9/L、(58.1±9.3)%、(2659.4±885.2)ng/L、(111.8±46.6)ng/L]轻度降低,但差异无统计学意义(P均〉0.05);血清CRP、IL-6和TC、LDL—C水平显著减低[治疗前分别为(4.3±3.7)mg/L、(4.8±2.0)ng/L、(4.2±1.0)mmol/L、(2.4±0.5)mmol/L;治疗后分别为(2.6±1.8)mg/L、(4.7±1.9)ng/L、(3.7±0.8)mmol/L、(2.2±0.5)mmol/L,P均〈0.05],IL一8浓度轻度降低[(6.2±1.8)ng/L与(6.4±1.9)ng/L],但差异无统计学意义(P〉0.05);SGRQ各项分值中症状评分明显减低[(39.6±10.8)分与(32.3±11.6)分,P〈0.05],其他观察项目(SNOT-20量表评分、肺功能)改善不明显(P均〉0.05)。常规治疗组所有炎症指标及生活质量评分、肺功能均无显著改善(P均〉0.05)。结论辛伐他汀可减轻COPD患者全身性炎症反应并缓解症状。
Objective To investigate the influence of simvastatin on inflammatory indices in nasal lavage, sputum and blood and clinical index in patients with chronic obstructive pulmonary diseases (COPD). Methods Thirty-seven stable COPD patients were randomly divided into simvastatin-treatment group ( n = 17 ), orally given simvastatin tablets for 4 weeks in addition to basic therapy ,40 mg, qd) and control group (n = 20 ), given usual med- ication). Total cell counts, percentage of leukocytes (N%) and levels of interleukin IL-8, IL-6 in nasal lavage and sputum at pre-post-treatment were compared ; Serum C-reactive protein ( CRP), total cholesterol ( TC ), low-density lipoprotein-cholesterol (LDL-C) as well as IL-8, IL-6 concentrations were measured, the variation of lung function, Sino-Nasal Outcome Test 20(SNOT-20) and St George's Respiratory Questionnaire(SGRQ) score were analyzed. Results After the treatment, the nasal lavage and sputum total cell counts, N% , IL-8 and IL-6 levels [ nasal lavage: (0.7 ±0.3) ×10^7/L,(41.1 ±10.9)% ,(105.8 ±74.5)ng/L,(3.8 ± 1.6)ng/L;sputum: (0.8 ±0.3) ×10^9/L, (56.6 ±9.6)%, (2565.5 ± 831.9) ng/L, ( 109.8 ±42.3) ng/L] dropped slightly in the simvastatin group compared with that at pretreatment [ nasal lavage : ( 0.8 ± 0.3 ) × 10^7/L, (43.2 ± 10. 8 ) %, ( 107.6 ± 86.3 ) ng/L, (4.1 ± 1.9 ) ng/L ; sputum : ( 0.8 ± 0.3 ) × 10^9/L、 ( 58. 1 ± 9.3 ) %, ( 2659.4 ± 885.2 ) ng/L, ( 111.8 ± 46.6 ) ng/L ] ( P 〉 0.05 ) ; There were significant decreases in serum CRP [ ( 4.3 ± 3.7 ) mg/L vs ( 2.6 ± 1.8 ) mg/L ], IL-6 [ (4.8 ±2.0) ng/L vs(4.7 ± 1.9) ng/L] ,TC[ (4.2 ± 1.0) mmol/L vs(3.7 ±0.8) mmol/L] ,LDL-C[ (2.4 ±0.5 ) mmot/L vs ( 2.2 ± 0.5 ) mmot/L ] ( P 〉 0.05 ) ; IL-8 concentrations in serum were lower gently [ ( 6.2 ± 1.8 ) ng/L vs (6.4 ± 1.9 ) ng/L ] (P 〉 0.05 ). Significant change of simvastatin treatment on SGRQ was only reflected in the symptom score[ pre-post-treatment :39.6 ± 10.8 vs 32.3 ± 11.6, P 〈 0.05, respectively ], while other observation items (SNOT-20, FEV1% , FEV1/FVC) changed not notably (P 〉 0.05 ). No marked changes in inflammatory markers and quality of life scores,lung function were observed in control group ( P 〉 0.05 ). Conclusion Simvastatin may be associated with the potential to alleviate systemic inflammation and relieve symptoms in COPD patients.
出处
《中国综合临床》
2009年第7期695-698,共4页
Clinical Medicine of China
基金
中华医学会临床医学科研专项资金资助课题(07010110019)
关键词
慢性阻塞性肺疾病
辛伐他汀
炎症
SNOT-20评分
SGRQ评分
Chronic obstructive pulmonary disease
Simvastatin
Inflammation
Sino-Nasal outcome test-20
St George's Respiratory Questionnaire